Avoid common mistakes on your manuscript.
With limited evidence, the benefit of adjuvant chemotherapy (AT) after completion of neoadjuvant chemotherapy (NT) and surgical resection in patients with pancreatic adenocarcinoma is debated. The National Cancer Database from 2006 to 2015 was used to identify patients undergoing NT. Results of this study (http://doi.org/10.1245/s10434-020-09546-8) suggest that, in patients with pancreatic adenocarcinoma, additional adjuvant chemotherapy is beneficial in subgroups with low-risk pathologic features who have undergone neoadjuvant chemotherapy and surgical resection.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Olecki, E.J., Stahl, K.A., Torres, M.B. et al. ASO Visual Abstract: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival in Those with Low-Risk Pathology. Ann Surg Oncol 28, 3124 (2021). https://doi.org/10.1245/s10434-021-09764-8
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-09764-8